Advertisement
Document › Details
Vividion Therapeutics, Inc.. (4/30/19). "Press Release: Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing". San Diego, CA.
> Bolsters capital to advance lead programs into the clinic and broaden early-stage pipeline of therapeutics against previously intractable drug targets
> Financing round led by Nextech Invest
Vividion Therapeutics, a biotechnology company with a revolutionary platform to discover small molecule therapeutics against biologically compelling but previously intractable targets, today announced the completion of an oversubscribed $82 Million Series B financing. The financing was led by Nextech Invest, an oncology-focused investment firm, and included participation from additional new investors BVF Partners, Casdin Capital, Mubadala Ventures, Trinitas Capital, Mirae Asset Capital, Altitude Life Science Ventures, and Alexandria Venture Investments. Existing investors ARCH Venture Partners, Versant Ventures, Cardinal Partners and Celgene Corporation also participated in the round.
In connection with the financing, Jakob Loven, Ph.D., Partner at Nextech Invest, will join the Vividion Board of Directors.
"Vividion's unique approach has allowed us to discover and advance exquisitely selective small molecules against high value targets that have been extremely challenging to drug historically," said Dr. Diego Miralles, Chief Executive Officer of Vividion Therapeutics. "With over $165 million in cash and a remarkable team, we are well positioned with substantial runway to maximize the multiple opportunities provided by our unique platform, bringing therapeutics to many patients in need."
Vividion Therapeutics has pioneered an approach, based on the work of Professor Benjamin Cravatt at The Scripps Research Institute, that enables screening of small molecules against every protein in native biological systems. This unique platform identifies highly selective binders to previously intractable targets, agnostic to protein class and function. These can be developed into drugs utilizing a range of approaches, including direct and allosteric modulation of protein function, and targeted protein degradation. The company's immediate focus is in oncology and immunology.
"We are witnessing a renaissance in the field of synthetic and medicinal chemistry and the numerous possibilities small molecule drug discovery brings to previously challenging target classes," said Loven. He added: "Vividion has successfully pioneered its platform to reveal druggable opportunities at an unprecedented scale and resolution to open a large range of therapeutic possibilities. We look forward to working with Vividion's highly experienced team as they continue to build the platform and pipeline toward first-in-class medicines for underserved patients."
About Vividion
Vividion Therapeutics is a biotechnology company focused on developing innovative therapeutics that treat major unmet medical needs using the first platform for proteome-wide small molecule drug discovery. The company's cutting-edge platform is based on seminal work from the labs of Professors Benjamin Cravatt, Phil Baran, and Jin-Quan Yu at The Scripps Research Institute in La Jolla, CA. Vividion previously raised a $45 Million Series A from ARCH Venture Partners, Versant Ventures, and Cardinal Partners. In March 2018, the Company established a multi-year, $101 Million up-front strategic collaboration with Celgene Corporation, aimed at discovering therapeutics against select first-in-class targets, with an initial focus in oncology and inflammation.
Vividion Therapeutics is headquartered in San Diego, CA. For more information, visit www.vividion.com.
Record changed: 2023-06-05 |
Advertisement
More documents for Bayer (Group)
- [1] BenevolentAI Ltd.. (1/24/24). "Press Release: BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer". London....
- [2] Bayer AG. (10/10/23). "Press Release: Bayer Invests 250 million USD in New Cell Therapy Manufacturing Facility in the U.S. [Not intended for US and UK Media]". Berlin....
- [3] Twist Bioscience Corporation. (10/5/23). "Press Release: Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million". Hamburg & Singapore....
- [4] Bayer AG. (9/21/23). "Press Release: Bayer to Collaborate with Hologic in Breast cancer Imaging [Not intended for U.S. and UK Media]". Berlin....
- [5] Bayer AG. (8/30/23). "Press Release: Strong Commitment to Modern Crop Protection Made in Europe. Bayer to Invest EUR 220 Million in New R&D Facility at Its Monheim Site". Monheim....
- [6] Bayer AG. (8/29/23). "Press Release: Gene Editing – Pairwise and Bayer Start New Five-year Multi-million Dollar Collaboration to Further Advance Short-stature Corn". Durham, NC & Monheim....
- [7] BlueRock Therapeutics LP. (8/23/23). "Press Release: BlueRock’s Phase I Study with Bemdaneprocel in Patients with Parkinson’s Disease Meets Primary Endpoint". Wuppertal....
- [8] Bayer AG. (8/22/23). "Press Release: Bayer Appoints Dr. Juergen Eckhardt as New Head of Pharmaceuticals Business Development & Licensing / Open Innovation". Berlin....
- [9] Lena Biosciences, Inc.. (8/7/23). "Press Release: Lena Biosciences Appoints Dr. Eckhard von Keutz to Its Business Advisory Board and Science Advisory Board"....
- [10] Bayer AG. (6/5/23). "Press Release: Bayer Strengthens Gene Therapy Portfolio with Lipid Nanoparticle Technology from Acuitas Therapeutics [Not intended for U.S. and UK Media]". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top